Immunotherapy Trials Jump to 4,591 in 10 Years, Expanding Beyond 30 Cancer Types
Updated
Updated · The Guardian · May 23
Immunotherapy Trials Jump to 4,591 in 10 Years, Expanding Beyond 30 Cancer Types
3 articles · Updated · The Guardian · May 23
Summary
4,591 immunotherapy trials were logged globally in the past decade, up from 1,257 between 2006 and 2016, as researchers pushed immune-based treatments into cancer, allergies, infections and autoimmune disease.
Dozens of cancer immunotherapies are already approved across more than 30 tumour types, including checkpoint inhibitors, antibody drugs, CAR-T therapies and more than 100 cancer vaccines now in trials.
Thousands of patients with breast, bladder, kidney and skin cancer are being recruited into a four-year study launched last week to explain why some patients respond strongly while others barely benefit.
Outside cancer, newer approaches aim to calm overactive immunity, from allergy desensitisation and a small depression trial using tocilizumab to regulatory T-cell therapies being developed for multiple sclerosis, inflammatory bowel disease, dementia and lupus.
Researchers say the boom reflects a broader shift in medicine: immune dysfunction is increasingly seen as a driver of ageing, inflammation and chronic disease, making immunotherapy a platform rather than a niche treatment class.
Beyond cancer, could engineering immune cells inside the body soon offer cures for chronic diseases like dementia, type 1 diabetes, or lupus?
A recent breakthrough showed cheaper 'in vivo' CAR-T is possible. What are the key safety hurdles preventing this from becoming widely available?
With immunotherapies failing most patients, can AI predict who will benefit versus who may suffer fatal side effects before treatment even begins?
Immunotherapy 2024–2026: Breakthroughs, Precision Strategies, and the Global Push for Equitable Cancer Cures
Overview
Between 2024 and 2026, immunotherapy saw rapid progress, driven by years of research and innovation. This period featured explosive growth in clinical trials and a wave of regulatory approvals, highlighting the expanding utility of immunotherapy. Therapeutic strategies diversified beyond traditional immune checkpoint inhibitors, with new treatments like Elahere gaining approval for specific cancer types after showing better outcomes in clinical trials. These advances reflect a shift toward more personalized and effective cancer therapies, marking a significant milestone in the fight against cancer.